Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending March 17, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the company's own ordinary shares, executed under authority granted by shareholders at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital movements.
- Shares Repurchased: 4,000,000 ordinary shares.
- Repurchase Price: 1,014.05 pence per share.
- Treasury Shares Held: 504,194,158 shares (representing 9.28% of total voting rights).
- Shares in Issue: 5,434,994,058 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the company's share capital through the cancellation of 4,000,000 repurchased shares. Consequently, the total number of shares in issue stands at 5,434,994,058, which serves as the denominator for shareholder notification calculations under the Financial Services Authority's Disclosure and Transparency Rules.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the updated total number of shares in issue (5,434,994,058) for accurate calculation of ownership percentages.
- Confirm the current percentage of Treasury shares held by the company (9.28% of total voting rights).
- Review the Financial Services Authority's Disclosure and Transparency Rules to determine if the updated share count triggers any notification requirements for significant shareholders.